Feasibility, Phase I, and Pharmacological Study of Aerosolized Liposomal 9-Nitro-20(S)-Camptothecin in Patients with Advanced Malignancies in the Lungs

Saved in:
Bibliographic Details
Published inAnnals of the New York Academy of Sciences Vol. 922; no. 1; pp. 352 - 354
Main Authors VERSCHRAEGEN, C. F., GILBERT, B. E., HUARINGA, A. J., NEWMAN, R., HARRIS, N., LEYVA, F. J., KEUS, L., CAMPBELL, K., NELSON-TAYLOR, T., KNIGHT, V.
Format Journal Article
LanguageEnglish
Published Oxford, UK Blackwell Publishing Ltd 01.01.2000
Subjects
Adult
Aerosols
Aged
Antineoplastic Agents - administration & dosage
Antineoplastic Agents - adverse effects
Antineoplastic Agents - pharmacokinetics
Camptothecin - administration & dosage
Camptothecin - adverse effects
Camptothecin - analogs & derivatives
Camptothecin - pharmacokinetics
Drug Administration Schedule
Feasibility Studies
Female
Humans
Liposomes
Lung Neoplasms - drug therapy
Lung Neoplasms - metabolism
Male
Middle Aged
Online AccessGet full text

Cover

More Information
Bibliography:istex:52F777A92514F186AEE10B59C186A54CD8694388
ark:/67375/WNG-87HBRG8D-N
ArticleID:NYAS352
ISSN:0077-8923
1749-6632
DOI:10.1111/j.1749-6632.2000.tb07063.x